Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Carter

Showing results (841-850 of 872) with videos related to

Pageof 88
Sort By:
ACS Medicinal Chemistry Letters|March 21, 2019
Identification of Imidazo[1,2-<i>b</i>]pyridazine Derivatives as Potent, Selective, and Orally Active Tyk2 JH2 InhibitorsChunjian Liu, James Lin, Ryan Moslin, et al.
Bioorganic & Medicinal Chemistry Letters|April 9, 2016
Identification and synthesis of potent and selective pyridyl-isoxazole based agonists of sphingosine-1-phosphate 1 (S1P1)Junqing Guo, Scott H Watterson, Steven H Spergel, et al.
The Journal of Clinical Investigation|September 6, 2007
Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicityJeremy R Graff, Bruce W Konicek, Thomas M Vincent, et al.
Leukemia|September 11, 2014
Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemiaC Niederwieser, J Kohlschmidt, S Volinia, et al.
Journal of Medicinal Chemistry|August 8, 2014
Discovery of the CCR1 antagonist, BMS-817399, for the treatment of rheumatoid arthritisJoseph B Santella, Daniel S Gardner, John V Duncia, et al.
ACS Medicinal Chemistry Letters|March 21, 2019
Use of a Conformational-Switching Mechanism to Modulate Exposed Polarity: Discovery of CCR2 Antagonist BMS-741672Michael G Yang, Zili Xiao, Robert J Cherney, et al.
Journal of Medicinal Chemistry|July 19, 2019
Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165Stephen T Wrobleski, Ryan Moslin, Shuqun Lin, et al.
Cancer Research|May 20, 2016
Stromal-Based Signatures for the Classification of Gastric CancerMark T Uhlik, Jiangang Liu, Beverly L Falcon, et al.
ACS Medicinal Chemistry Letters|March 18, 2016
Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P1 Receptor Modulator in Clinical TrialsT G Murali Dhar, Hai-Yun Xiao, Jenny Xie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 2014
Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene scoreGuido Marcucci, Pearlly Yan, Kati Maharry, et al.
Pageof 88

Showing results (841-850 of 872) with videos related to

Sort By:
Pageof 88
ACS Medicinal Chemistry Letters|March 21, 2019
Identification of Imidazo[1,2-<i>b</i>]pyridazine Derivatives as Potent, Selective, and Orally Active Tyk2 JH2 InhibitorsChunjian Liu, James Lin, Ryan Moslin, et al.
Bioorganic & Medicinal Chemistry Letters|April 9, 2016
Identification and synthesis of potent and selective pyridyl-isoxazole based agonists of sphingosine-1-phosphate 1 (S1P1)Junqing Guo, Scott H Watterson, Steven H Spergel, et al.
The Journal of Clinical Investigation|September 6, 2007
Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicityJeremy R Graff, Bruce W Konicek, Thomas M Vincent, et al.
Leukemia|September 11, 2014
Prognostic and biologic significance of DNMT3B expression in older patients with cytogenetically normal primary acute myeloid leukemiaC Niederwieser, J Kohlschmidt, S Volinia, et al.
Journal of Medicinal Chemistry|August 8, 2014
Discovery of the CCR1 antagonist, BMS-817399, for the treatment of rheumatoid arthritisJoseph B Santella, Daniel S Gardner, John V Duncia, et al.
ACS Medicinal Chemistry Letters|March 21, 2019
Use of a Conformational-Switching Mechanism to Modulate Exposed Polarity: Discovery of CCR2 Antagonist BMS-741672Michael G Yang, Zili Xiao, Robert J Cherney, et al.
Journal of Medicinal Chemistry|July 19, 2019
Highly Selective Inhibition of Tyrosine Kinase 2 (TYK2) for the Treatment of Autoimmune Diseases: Discovery of the Allosteric Inhibitor BMS-986165Stephen T Wrobleski, Ryan Moslin, Shuqun Lin, et al.
Cancer Research|May 20, 2016
Stromal-Based Signatures for the Classification of Gastric CancerMark T Uhlik, Jiangang Liu, Beverly L Falcon, et al.
ACS Medicinal Chemistry Letters|March 18, 2016
Identification and Preclinical Pharmacology of BMS-986104: A Differentiated S1P1 Receptor Modulator in Clinical TrialsT G Murali Dhar, Hai-Yun Xiao, Jenny Xie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 2014
Epigenetics meets genetics in acute myeloid leukemia: clinical impact of a novel seven-gene scoreGuido Marcucci, Pearlly Yan, Kati Maharry, et al.
Pageof 88